Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, eribulin (Halaven®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. |
||
|
||
Medicine details |
||
| Medicine name | eribulin (Halaven®) | |
| Formulation | 0.44 mg/ml solution for injection | |
| Reference number | 979 | |
| Indication | Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease |
|
| Company | Eisai Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/09/2016 | |